ZYSM005

ZYSM005 is a small molecule inhibitor developed by Yantai Rongchang Pharmaceutical that specifically targets the active (ON-state) of the KRAS G12D mutant protein. KRAS G12D is a common oncogenic driver mutation found in a variety of solid tumors, most notably in pancreatic, colorectal, and lung cancers. Unlike many first-generation KRAS inhibitors that bind to the inactive (OFF-state) of the protein, ZYSM005 is designed to bind to the GTP-bound active form, potentially providing more direct and potent inhibition of downstream signaling pathways. The program is currently in the lead optimization and preclinical candidate (PCC) selection stage for the treatment of advanced solid tumors.